Tony Butler
Stock Analyst at EF Hutton
(1.41)
# 2,441
Out of 4,412 analysts
102
Total ratings
36.63%
Success rate
-12.89%
Average return
Main Sectors:
Top Industries:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Reiterates: Buy | $16 | $2.88 | +455.56% | 5 | Aug 10, 2023 | |
| ADAP Adaptimmune Therapeutics | Reiterates: Buy | $10 | $1.08 | +830.23% | 8 | Aug 10, 2023 | |
| FATE Fate Therapeutics | Reiterates: Buy | $10 | $3.80 | +163.16% | 4 | Aug 9, 2023 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Buy | $75 | $53.91 | +39.12% | 7 | Aug 8, 2023 | |
| MRUS Merus | Reiterates: Buy | $35 | $45.04 | -22.29% | 7 | Aug 8, 2023 | |
| GTBP GT Biopharma | Reiterates: Hold | $60 | $3.35 | +1,693.72% | 5 | Aug 7, 2023 | |
| CGEN Compugen | Reiterates: Buy | $13 | $1.92 | +577.08% | 6 | Aug 7, 2023 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $50 | $22.73 | +119.97% | 5 | Aug 3, 2023 | |
| ALLO Allogene Therapeutics | Reiterates: Buy | $15 | $2.89 | +419.03% | 7 | Aug 3, 2023 | |
| GTHX G1 Therapeutics | Reiterates: Buy | $19 | $3.99 | +376.19% | 4 | Aug 2, 2023 | |
| BCAB BioAtla | Reiterates: Buy | $25 | $2.54 | +884.25% | 6 | Aug 2, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $43 | $10.78 | +298.89% | 3 | Aug 1, 2023 | |
| PYXS Pyxis Oncology | Initiates: Buy | $15 | $4.30 | +248.84% | 1 | Jul 31, 2023 | |
| VIRX Viracta Therapeutics | Initiates: Buy | $10 | $0.83 | +1,107.29% | 1 | Jul 31, 2023 | |
| CVM CEL-SCI | Reiterates: Buy | $10 | $1.44 | +594.44% | 3 | Jul 12, 2023 | |
| CALC CalciMedica | Reiterates: Buy | $17 | $5.45 | +211.93% | 2 | Jul 7, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $11.69 | +1,320.02% | 4 | Jul 3, 2023 | |
| REPL Replimune Group | Reiterates: Buy | $60 | $6.42 | +834.58% | 4 | Jun 7, 2023 | |
| INAB IN8bio | Reiterates: Buy | $8 | $1.04 | +669.23% | 4 | Jun 5, 2023 | |
| VNRX VolitionRx | Assumes: Buy | $6 | $0.91 | +556.67% | 1 | Jun 1, 2023 | |
| HCWB HCW Biologics | Assumes: Buy | $9 | $1.40 | +542.90% | 1 | Jun 1, 2023 | |
| OCEA Ocean Biomedical | Assumes: Buy | $17 | $1.34 | +1,168.66% | 1 | May 25, 2023 | |
| BCEL Atreca | Reiterates: Buy | $10 | $0.08 | +12,400.00% | 2 | Mar 30, 2023 | |
| ATRA Atara Biotherapeutics | Initiates: Buy | $25 | $0.69 | +3,523.19% | 1 | Jan 5, 2023 | |
| GNTA Genenta Science | Initiates: Buy | $15 | $2.59 | +479.15% | 1 | Jan 5, 2023 | |
| MRKR Marker Therapeutics | Downgrades: Neutral | $30 → $10 | $4.29 | +133.10% | 1 | Feb 17, 2022 | |
| CMPX Compass Therapeutics | Initiates: Buy | n/a | $1.45 | - | 1 | Nov 19, 2021 | |
| TBIO Telesis Bio | Maintains: Neutral | n/a | $0.32 | - | 3 | Aug 4, 2021 | |
| NTLA Intellia Therapeutics | Maintains: Buy | n/a | $20.76 | - | 2 | Jun 28, 2021 | |
| PBLA Panbela Therapeutics | Initiates: Buy | $240,000 | $0.41 | +58,536,485.37% | 1 | Jun 28, 2021 | |
| NXTC NextCure | Initiates: Buy | n/a | $1.35 | - | 1 | Mar 2, 2020 |
Century Therapeutics
Aug 10, 2023
Reiterates: Buy
Price Target: $16
Current: $2.88
Upside: +455.56%
Adaptimmune Therapeutics
Aug 10, 2023
Reiterates: Buy
Price Target: $10
Current: $1.08
Upside: +830.23%
Fate Therapeutics
Aug 9, 2023
Reiterates: Buy
Price Target: $10
Current: $3.80
Upside: +163.16%
CRISPR Therapeutics AG
Aug 8, 2023
Reiterates: Buy
Price Target: $75
Current: $53.91
Upside: +39.12%
Merus
Aug 8, 2023
Reiterates: Buy
Price Target: $35
Current: $45.04
Upside: -22.29%
GT Biopharma
Aug 7, 2023
Reiterates: Hold
Price Target: $60
Current: $3.35
Upside: +1,693.72%
Compugen
Aug 7, 2023
Reiterates: Buy
Price Target: $13
Current: $1.92
Upside: +577.08%
Bicycle Therapeutics
Aug 3, 2023
Reiterates: Buy
Price Target: $50
Current: $22.73
Upside: +119.97%
Allogene Therapeutics
Aug 3, 2023
Reiterates: Buy
Price Target: $15
Current: $2.89
Upside: +419.03%
G1 Therapeutics
Aug 2, 2023
Reiterates: Buy
Price Target: $19
Current: $3.99
Upside: +376.19%
BioAtla
Aug 2, 2023
Reiterates: Buy
Price Target: $25
Current: $2.54
Upside: +884.25%
Biomea Fusion
Aug 1, 2023
Reiterates: Buy
Price Target: $43
Current: $10.78
Upside: +298.89%
Pyxis Oncology
Jul 31, 2023
Initiates: Buy
Price Target: $15
Current: $4.30
Upside: +248.84%
Viracta Therapeutics
Jul 31, 2023
Initiates: Buy
Price Target: $10
Current: $0.83
Upside: +1,107.29%
CEL-SCI
Jul 12, 2023
Reiterates: Buy
Price Target: $10
Current: $1.44
Upside: +594.44%
CalciMedica
Jul 7, 2023
Reiterates: Buy
Price Target: $17
Current: $5.45
Upside: +211.93%
Agenus
Jul 3, 2023
Reiterates: Buy
Price Target: $166
Current: $11.69
Upside: +1,320.02%
Replimune Group
Jun 7, 2023
Reiterates: Buy
Price Target: $60
Current: $6.42
Upside: +834.58%
IN8bio
Jun 5, 2023
Reiterates: Buy
Price Target: $8
Current: $1.04
Upside: +669.23%
VolitionRx
Jun 1, 2023
Assumes: Buy
Price Target: $6
Current: $0.91
Upside: +556.67%
HCW Biologics
Jun 1, 2023
Assumes: Buy
Price Target: $9
Current: $1.40
Upside: +542.90%
Ocean Biomedical
May 25, 2023
Assumes: Buy
Price Target: $17
Current: $1.34
Upside: +1,168.66%
Atreca
Mar 30, 2023
Reiterates: Buy
Price Target: $10
Current: $0.08
Upside: +12,400.00%
Atara Biotherapeutics
Jan 5, 2023
Initiates: Buy
Price Target: $25
Current: $0.69
Upside: +3,523.19%
Genenta Science
Jan 5, 2023
Initiates: Buy
Price Target: $15
Current: $2.59
Upside: +479.15%
Marker Therapeutics
Feb 17, 2022
Downgrades: Neutral
Price Target: $30 → $10
Current: $4.29
Upside: +133.10%
Compass Therapeutics
Nov 19, 2021
Initiates: Buy
Price Target: n/a
Current: $1.45
Upside: -
Telesis Bio
Aug 4, 2021
Maintains: Neutral
Price Target: n/a
Current: $0.32
Upside: -
Intellia Therapeutics
Jun 28, 2021
Maintains: Buy
Price Target: n/a
Current: $20.76
Upside: -
Panbela Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $240,000
Current: $0.41
Upside: +58,536,485.37%
NextCure
Mar 2, 2020
Initiates: Buy
Price Target: n/a
Current: $1.35
Upside: -